Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$106.45 USD

106.45
1,174,113

-0.63 (-0.59%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $107.09 +0.64 (0.60%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Novartis (NVS) CAR-T Therapy Kymriah Receives FDA Approval

by Zacks Equity Research

Novartis AG (NVS) gets a major boost as the FDA approved its breakthrough gene transfer treatment, Kymriah for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL).

    Roche's (RHHBY) Actemra Gets FDA Nod for Label Expansion

    by Zacks Equity Research

    Roche Holding AG's (RHHBY) drug Actemra got FDA approval for label expansion.

      Ryan McQueeney headshot

      Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap

      by Ryan McQueeney

      The cancer treatment industry is celebrating a massive victory on Wednesday, as Novartis (NVS) received approval for its innovative new lymphoblastic leukemia treatment, making it the first approved CAR-T therapy in the world.

        Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe

        by Zacks Equity Research

        Pfizer (PFE) along with Avillion announced that the regulatory authorities in the U.S. and Europe have accepted the application for label expansion of Bosulif to include newly diagnosed patients.

          The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

          by Zacks Equity Research

          The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

            Gilead to Fly High with Kite Pharma Acquisition for $11.9B

            by Zacks Equity Research

            Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy.

              Novartis Announces Positive Data on Cardiovascular Drug

              by Zacks Equity Research

              Novartis AG (NVS) announced positive primary data on pipeline candidate canakinumab (ACZ885).

                Swarup Gupta headshot

                Foreign Stock Roundup: WPP 1H17, BHP Billiton Fiscal 2017 Results Impress

                by Swarup Gupta

                Foreign markets remained focused on the outcome of the annual economic symposium at Jackson Hole last week.

                  Mylan and Otsuka Ink Agreement to Commercialize Deltyba

                  by Zacks Equity Research

                  Mylan (MYL) and Otsuka Pharmaceutical have entered into a license agreement to commercialize Deltyba in developing countries.

                    Novartis (NVS) Receives EC Approval for Breast Cancer Drug

                    by Zacks Equity Research

                    Novartis AG (NVS) obtained approval for its breast cancer drug Kisqali in Europe.

                      Kite Pharma at New 52-Week High: What's Driving the Stock?

                      by Zacks Equity Research

                      Kite Pharma (KITE) shares hit a new 52-week high as the company's CAR-T therapy with axicabtagene ciloleucel nears an FDA nod. It has also filed regulatory application for the candidate in the EU.

                        Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View

                        by Zacks Equity Research

                        Lannett (LCI) reported in-line Q4 earnings and sales. The FDA approved multiple pending ANDAs during the quarter. Also, the company provided strong outlook for 2018.

                          Why Have Mylan's (MYL) Shares Lost 19.4% So Far This Year?

                          by Zacks Equity Research

                          Shares of Mylan N.V. (MYL) have lost almost 19.4% in the year so far given the competitive pressure.

                            Are Glaxo's Successful New Drugs Enough to Drive Growth?

                            by Zacks Equity Research

                            Despite the success of new products, GlaxoSmithKline plc (GSK) believes that its overall performance has been weaker than it would have liked.

                              Arpita Dutt headshot

                              4 Biotech Stocks to Add to your Portfolio Post Q2 Earnings

                              by Arpita Dutt

                              Here is a look at four biotech stocks including Gilead (GILD) that topped estimates in Q2 and are witnessing upward estimate revisions for the current year.

                                Arpita Dutt headshot

                                Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why

                                by Arpita Dutt

                                Late last week, Biogen (BIIB) and six other pharma and biotech stocks were in the news due to the pricing of their multiple sclerosis ("MS") drugs.

                                  Can Pfizer Bank on New Immunotherapy Bavencio for Growth?

                                  by Zacks Equity Research

                                  Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.

                                    Ophthotech's Fovista Combo Regimen Disappoints in Phase III

                                    by Zacks Equity Research

                                    Ophthotech (OPHT) disappoints with poor evaluation of Fovista combined with Eylea or Avastin for treatment of AMD in phase III. The study misses the primary endpoint.

                                      Can Ligand's Captisol Deals Boost Growth in the Long Run?

                                      by Zacks Equity Research

                                      Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, earning milestones and royalty payments from the same.

                                        Catalyst (CPRX) Focused on Development of Pipeline Candidates

                                        by Zacks Equity Research

                                        Catalyst Pharmaceuticals, Inc. (CPRX) focuses on the development of its pipeline candidates Firdapse and CPP-115.

                                          Are Amgen's New Drugs Doing Well Enough to Drive Sales?

                                          by Zacks Equity Research

                                          Higher volumes of Amgen, Inc.'s (AMGN) new products may not be enough to offset the lost sales due to the decline in mature brands.

                                            The Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss

                                            by Zacks Equity Research

                                            The Medicines Company (MDCO) reports wider-than-expected loss with revenues missing estimates. The top line also decreases year over year due to low Angiomax sales.

                                              Kite Pharma (KITE) Q2 Loss Narrower than Expected, Shares Up

                                              by Zacks Equity Research

                                              Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the second quarter of 2017 and beat estimates for sales. Shares of the biotech company rose 5.8% on Tuesday.

                                                Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised

                                                by Zacks Equity Research

                                                Ligand's (LGND) earnings and revenues beat estimates. Total revenue also rises year over on the back of higher royalty benefits. The company ups its outlook for 2017.

                                                  Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass

                                                  by Zacks Equity Research

                                                  Juno Therapeutics (JUNO) reports wider-than-expected loss but revenues beat estimates. However, revenue decreased year-over-year.